# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jackie Robinson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML037-SYN-TD
- Date: 1971-07-29
- Fictional facility: St. Posthumous Health Center
- Fictional author: Marcus Delacroix-Hale, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Review after the retina consultation and first eye injections: retinal diagnosis, glucose, blood pressure and kidney medicines. **S**

## History of present illness

Mr. Robinson returns two days after his first visit, from the retina clinic this morning. Dr. Ostrowski-Lane examined both eyes with dilating drops, used ultrasound to confirm that the right retina is attached behind the blood, and measured the swelling at the center of each retina by OCT. She found proliferative diabetic retinopathy in both eyes with swelling of the macula in both, and bleeding into the gel of the right eye, and gave the first aflibercept injections in both eyes. His eyes are a little sore, as expected. He had no flashes or curtain over his vision. He asked how quickly his sugar should come down, because he wants it fixed at once, and what the injections will do. Chest tightness on stairs is unchanged; the stress test is booked. **S**

| Element | Detail |
|---|---|
| Retina clinic | Proliferative retinopathy with macular edema in both eyes, right vitreous hemorrhage, retina attached; first injections given |
| Symptoms | Mild eye soreness; no flashes or curtain |
| Chest | Tightness on stairs unchanged; stress test booked |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Eyes | Positive | Blurred vision; mild soreness after the injections; no flashes |
| Cardiovascular | Positive | Chest tightness on stairs, easing with rest; calf pain after a block |
| Endocrine | Negative | No low blood sugar |
| Psychiatric | Positive | Grieving; sleeps poorly |

4 systems reviewed. **S**

## Current medications

- Metformin 1,000 mg oral tablet, one tablet twice daily with meals **S**
- Insulin glargine 100 units/mL pen, 30 units at bedtime, adjusted by the written plan: 2 units each week while fasting glucose is above 160 mg/dL, and 4 units less for any reading below 70 **S**
- Atorvastatin 80 mg oral tablet, one tablet daily (increased from 40 mg at intake) **S**
- Aspirin 81 mg delayed-release oral tablet, one tablet daily **S**
- Glucagon 3 mg nasal powder, one spray into the nose for severe low blood sugar; may repeat once after 15 minutes **S**
- Lisinopril 40 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating **S**
- Empagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating, and before surgery or a colonoscopy preparation **S**

## Allergies

- No known allergy **S**

## Objective

BP 148/90 mmHg; pulse 82 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 103.8 kg; BMI 32 kg/m². All vital signs are synthetic.

Best-corrected visual acuity, right eye (ETDRS letters): 35 (low); Best-corrected visual acuity, left eye (ETDRS letters): 56 (low); Central subfield thickness by OCT, right eye: 412 um (high); Central subfield thickness by OCT, left eye: 468 um (high). All results are synthetic.

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 148/90, pulse 82; weight 103.8 kg |
| Eyes | Mild redness at the injection sites; pupils dilated from the retina examination |
| Cardiovascular | Regular rhythm; no ankle swelling |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Proliferative diabetic retinopathy with center-involving macular edema, both eyes** (E11.3513). Vision-threatening disease in both eyes: best-corrected acuity 35 letters right and 56 left; central subfield 412 and 468 microns. Treatment has begun. **S**
   - Monthly aflibercept for three doses, then by response.
   - Laser to the right eye when the blood clears.
   - Low-vision evaluation booked.
   - Same-day return for a curtain over the vision, flashes or a sudden loss.
2. **Type 2 diabetes** (E11.65). A1c 10.4%. A rapid fall in A1c can briefly worsen proliferative retinopathy, and semaglutide was linked to more retinopathy complications in a cardiovascular trial; the aim is a steady fall of about one point every three months, with the retina specialist watching monthly. **S**
   - Continue metformin and the slow glargine titration plan.
   - Empagliflozin 10 mg daily.
   - A GLP-1 receptor agonist to be considered once the retina specialist judges the retina stable.
   - Talking glucose meter and large-print plan.
3. **Hypertension with chronic kidney disease** (I12.9). 148/90, above the goal below 130/80, with albuminuria. **S**
   - Lisinopril increased to 40 mg.
   - Potassium and creatinine in four weeks.
4. **Diabetic kidney disease with albuminuria** (E11.22). eGFR 79 with a urine albumin-to-creatinine ratio of 86 mg/g, raised also last year: G2 A2. An SGLT2 inhibitor and the highest ACE inhibitor dose protect kidneys and heart. **S**
   - Empagliflozin and lisinopril as above; written sick-day rules.
   - Urine albumin at three months.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure (seated, two readings, large cuff) | Every visit | Completed today | 148/90 |
| Examination | Weight and BMI | Every visit | Completed today | 103.8 kg, BMI 32.0 |
| Imaging | Retina care: acuity, OCT, injections and laser | Monthly at the retina clinic while treating | Completed today | Retina clinic today: acuity 35 letters right and 56 left; central subfield 412 and 468 microns; first injections both eyes |
| Laboratory | Hemoglobin A1c | Every 3 months while not at goal or after a change | Up to date | 10.4% two days ago; next at three months |
| Self-management | Glucose log and low blood sugar review (talking meter) | Every visit | Completed today | Readings 170 to 260 mg/dL; no lows; talking meter ordered |
| Laboratory | Potassium, creatinine and eGFR | Two to four weeks after starting or increasing an ACE inhibitor or SGLT2 inhibitor; then every 6 to 12 months | Ordered | Lisinopril increased and empagliflozin started today; check in four weeks |
| Laboratory | Urine albumin-to-creatinine ratio | Three to six months after a treatment change; then 1 to 4 times a year by risk | Up to date | 86 mg/g two days ago, raised also last year; next at three months |
| Laboratory | Lipid panel | 4 to 12 weeks after starting or changing a statin; then yearly | Due | Atorvastatin increased to 80 mg two days ago; due in 4 to 12 weeks |
| Medication safety | Medicine safety: low blood sugar, sick-day rules, genital infection, dizziness, cost | Every visit | Completed today | Sick-day rules for empagliflozin and lisinopril written in large print; genital hygiene advice; glucagon shown |
| Referral | Retina consultation | Within 48 hours for new floaters and vision loss with diabetes | Completed today | Seen by Dr. Ostrowski-Lane today |

## Goal progress

- Vision kept or improved: proliferative disease regressed and macular edema reduced on anti-VEGF injections and laser. In progress; target 1971-10-26. **S**
- A1c falling by about one point every three months without low blood sugar, to below 8% within six months and then below 7%. In progress; target 1971-10-26. **S**
- Blood pressure below 130/80 mmHg. In progress; target 1971-10-26. **S**
- LDL cholesterol below 55 mg/dL. In progress; target 1971-10-26. **S**
- Walk at least three blocks without stopping, through supervised exercise. In progress; target 1971-10-26. **S**
- Feet kept intact: daily foot checks he can do with low vision, protective footwear, and prompt care for any skin break. In progress; target 1971-10-26. **S**
- Grief acknowledged and supported, with depression screening repeated. In progress; target 1971-10-26. **S**

## Medication changes

- Stopped: Lisinopril 20 mg oral tablet, one tablet daily **S**
- Started: Lisinopril 40 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating **S**
- Started: Empagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating, and before surgery or a colonoscopy preparation **S**

## Guideline basis

- 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- Diabetic Retinopathy Preferred Practice Pattern (2025), American Academy of Ophthalmology (Ophthalmology 2025; Lim JI, et al.)
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) (2016), New England Journal of Medicine (Marso SP, et al.)
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (J Am Coll Cardiol 2025)
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney International)
- CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension, hyperlipidemia, ischemic heart disease, chronic kidney disease and depression monographs (2026), Aether Forge

## Follow-up

- Stress test as booked. Second injections and review in four weeks with potassium and creatinine and the ankle-brachial index. Call for a curtain over the vision, flashes, eye pain with redness, chest pain at rest, dizziness, or vomiting (hold empagliflozin and lisinopril that day). **S**
- Next scheduled visit 1971-08-26: four weeks after the new medicines: potassium and creatinine, blood pressure, ankle-brachial index, feet, mood, and the second eye injections. **S**
